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Background: miRNAs are master regulators of signaling pathways critically involved 
in asthma and are transferred between cells in extracellular vesicles (EV). We aimed 
to investigate whether the miRNA content of EV secreted by primary normal human 
bronchial epithelial cells (NHBE) is altered upon asthma development.
Methods: NHBE cells were cultured at air‐liquid interface and treated with interleu‐
kin (IL)‐13 to induce an asthma‐like phenotype. EV isolations by precipitation from 
basal culture medium or apical surface wash were characterized by nanoparticle 
tracking analysis, transmission electron microscopy, and Western blot, and EV‐asso‐
ciated miRNAs were identified by a RT‐qPCR‐based profiling. Significant candidates 
were confirmed in EVs isolated by size‐exclusion chromatography from nasal lavages 
of children with mild‐to‐moderate (n = 8) or severe asthma (n = 9), and healthy con‐
trols (n = 9).
Results: NHBE cells secrete EVs to the apical and basal side. 47 miRNAs were ex‐
pressed in EVs and 16 thereof were significantly altered in basal EV upon IL‐13 treat‐
ment. Expression of miRNAs could be confirmed in EVs from human nasal lavages. Of 
note, levels of miR‐92b, miR‐210, and miR‐34a significantly correlated with lung func‐
tion parameters in children (FEV1FVC%pred and FEF25‐75%pred), thus lower sEV‐miRNA 
levels in nasal lavages associated with airway obstruction. Subsequent ingenuity 
pathway analysis predicted the miRNAs to regulate Th2 polarization and dendritic 
cell maturation.
Conclusion: Our data indicate that secretion of miRNAs in EVs from the airway epi‐
thelium, in particular miR‐34a, miR‐92b, and miR‐210, might be involved in the early 
development of a Th2 response in the airways and asthma.
K E Y W O R D S
airway epithelium, asthma, extracellular vesicles, miRNA, Th2 polarization
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1  | INTRODUC TION
Worldwide, the incidence and prevalence of chronic inflammatory 
diseases including asthma are rapidly increasing, and the World 
Health Organization estimates 300 million people to be suffering 
from asthma.1 Thus, there is a huge and unmet need to develop novel 
therapies and preventative strategies. An important prerequisite for 
this is a detailed understanding of underlying molecular mechanisms.
The airway epithelium forms a first barrier between inhaled 
substances and the lung, allowing transmitting environmental sig‐
nals to the immune system which then mounts an appropriate re‐
sponse. This is crucial for maintaining the balance between defense 
against inhaled pathogens and tolerance toward innocuous aller‐
gens. Environmental stressors, such as virus infections or prote‐
ase‐containing allergens, may influence this system leading to the 
development of allergies, asthma, or other chronic lung diseases.2 
Interleukin (IL)‐33 and other pro‐inflammatory alarmins are released 
upon epithelial damage inducing a Th2 polarization by dendritic cells 
(DC).3 However, it is not yet clear if this is alone sufficient to induce 
the strong and persistent (DC‐mediated) Th2 immune response that 
is characteristic for allergic asthma. Thus, the epithelial‐immune 
cross talk in the lung microenvironment may additionally involve 
other players, such as extracellular vesicles (EVs).
EVs are subdivided in different classes according to size and intra‐
cellular origin, accordingly small EVs (sEVs) (50‐150 nm) and derived 
from multivesicular bodies of late endosomes are typically called 
exosomes.4 EVs can transfer microRNAs (miRNA) and express im‐
mune‐relevant surface molecules such as HLA‐DR or co‐stimulatory 
molecules, making them central players in the immune response.
5 
The EV‐associated miRNA content changes dynamically upon cel‐
lular stress or stimulation.6 and as miRNAs are master regulators of 
gene expression7 this can profoundly affect recipient cells. Several 
miRNAs are critically involved in asthma,8‐12 and levels within bron‐
choalveolar lavage fluid (BALF) of patients with asthma are different 
compared to healthy controls.13
Thus, we here aimed to elucidate if the EV‐associated miRNA se‐
cretion of the airway epithelium is involved in early asthma develop‐
ment. Therefore, we characterized the miRNA secretion in sEVs by 
primary normal bronchial epithelial cells (NHBE) treated with IL‐13 
to induce an asthma‐like epithelium, which was analysed by ingenu‐
ity pathway analysis (IPA) and confirmed in sEVs from human nasal 
lavages of children with asthma or healthy controls.
2  | MATERIAL AND METHODS
A detailed description of the cell culture, RT‐qPCR, Western blot and 
flow cytometry can be found in this article’s online supplement.
2.1 | Air‐liquid interface (ALI) culture of NHBE cells
Primary NHBE cells from three healthy individuals were purchased 
from Lonza (Basel, Switzerland) and cultured as previously de‐
scribed.9 ALI culture was performed on Collagen IV‐coated (Sigma 
Aldrich, St. Louis, USA) transwell inserts (Polyester, 0.4 µm pore size) 
(Costar, Washington DC, USA) for 28 days, with Pneumacult‐ALI 
(STEMCELL Technologies, Vancouver, Canada) containing 100 U/
ml penicillin and 0.1 mg/mL streptomycin (PAN Biotech, Aidenbach, 
G R A P H I C A L  A B S T R A C T
Primary human bronchial epithelial cells secrete microRNA‐containing extracellular vesicles (EV) apically and basally. Upon Interleukin‐13‐
induced goblet cell metaplasia, miR‐34a, miR‐92b, and miR‐210 levels in EVs are lower, which is predicted to influence dendritic cell 
maturation and Th2 polarization. Lower levels of these microRNAs in EVs in nasal lavages correlate with increased airway obstruction in 
children.
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Germany) and recombinant human IL‐13 in treated wells (5 ng/mL) 
(R&D systems, Minneapolis, USA).
2.2 | Histology of cross‐sectional membranes
After washing the surface with Hank’s Balanced Salt Solution 
(HBSS), cells were fixed by 4% paraformaldehyde (PFA) for 30 min‐
utes at RT. Membranes were stabilized in 2% agarose (Sigma Aldrich), 
dehydrated, and paraffin‐embedded. 1.5 µm membrane cross sec‐
tions was stained with Periodic acid‐Schiff (PAS) staining, indicating 
mucus in pink, as previously described.14
2.3 | RNA Isolation and real‐time quantitative 
polymerase chain reaction (RT‐qPCR)
Total miRNA‐enriched RNA was isolated from cells (miRNeasy Mini 
Kit, Qiagen, Venlo, the Netherlands) and EVs (miRNeasy Micro Kit) 
according to the manufacturer’s recommendations. mRNA was de‐
tected by SYBR green based RT‐qPCR (Roche, Mannheim, Germany) 
with specific primers (Table S1) on a Light Cycler 480II platform 
(Roche). For miRNA PCRs, 10 µL of each EV RNA sample was tran‐
scribed using the miScript RT‐qPCR system (Qiagen). Differences 
in expression were calculated by the ∆∆Ct method15 relative to a 
mean of the reference genes HPRT and YWHAZ or a miRNA ref‐
erence (here miR‐25 as it was found equally expressed). Graphs 
indicate dCp values (dCp = (Cptarget − Cpreference gene), lower value 
indicates higher expression, thus displayed on reversed y‐axis).
2.4 | EV precipitation
1 mL of basal medium or apical surface wash (500 µL of HBSS was 
added per 12‐well insert and then re‐collected) was incubated over‐
night at 4°C with 1/4th volume (250 µL) of ExoQuick‐TC reagent 
(System Biosciences, Paolo Alto, USA). EVs were pelleted the next 
day by centrifuging at 1500 g for 30 minutes.
2.5 | Nanoparticle tracking analysis
EVs were applied to a PMX 110 Scanning ZetaView (Particle Metrix, 
Meerbusch, Germany) in an appropriate dilution. Two video cycles 
were recorded at constant temperature and conductivity, each 
scanning 11 distinct positions in the cell cross section (30 frames/s). 
Recommended parameters (minimum brightness: 20, shutter: 70, 
sensitivity: 85, min size: 5 nm, max size: 1000 nm) were chosen, 
and results were analysed by ZetaView 8.04.02 SP2. Due to low 
EV counts, we did not include a threshold for completed traces. For 
NHBE experiments, a median of 47.50 ± 106.1 traces and for nasal 
lavages a median of 383.0 ± 598.8 traces was measured.
2.6 | Transmission electron microscopy
EVs were fixed in 2% PFA and bound to formvar/carbon‐coated 
200‐mesh nickel grids (Electron Microscopy Sciences, Hatfield, 
USA) for 15 minutes. Subsequently, grids were washed in PBS, fixed 
in 2.5% glutaraldehyde for 5 minutes and washed again in filtered 
water. EVs were negatively stained with 2% uranyl acetate for 1 min‐
utes, washed, and air‐dried overnight. Electron microscopy was 
performed on a Zeiss EM900 (Carl Zeiss Microscopy GmbH, Jena, 
Germany) with a wide‐angle dual‐speed 2K‐CCD camera at 80 kV.
2.7 | Western blot
EV proteins were isolated from 10 mL of pooled medium or apical 
washes according to16 by using 10× RIPA buffer (Merck Millipore, 
Burlington, USA) with protease inhibitors (complete Mini, Roche, 
Mannheim, Germany). We used the Bio‐Rad V3 Western blot work‐
flow (Bio‐Rad, Hercules, USA) including stain‐free technology and 
the primary antibodies anti‐CD63 (EPR5702) (Abcam, Cambridge, 
UK), anti‐CD9 (D3H4P), and anti‐Alix (E4T7U) (all rabbit, all Cell 
Signalling Technology. Danvers. USA) and secondary HRP‐con‐
jugated goat anti‐rabbit IgG antibody. Chemiluminescence signal 
was compared to total protein content by using ImageLab V5.2.1 
(Bio‐Rad).
2.8 | SeramiR miRNA profiling
EV RNA was profiled with the Human SeramiR Exosome RNA 
Profiling Kit (Systems Biosciences) according to the manufacturer’s 
recommendations. Due to low RNA content of EV samples hamper‐
ing reliable quantification, we used 10 µL of each sample for reverse 
transcription. Profiling PCRs were conducted in 96‐well plates on a 
Light Cycler 480 platform (Roche) using specific primers for 384 dif‐
ferent human miRNAs.
2.9 | Statistical analysis of miRNA profiling
Profiling data were analysed by the ∆∆Ct method and normalized 
to included spike‐in RNAs. Subsequently, we performed unpaired 
t tests with Benjamini‐Hochberg correction to adjust for multiple 
testing with the R package limma. An adjusted P‐value or false dis‐
covery rate (FDR) of ≤ 0.1 was set as cut‐off for subsequent analysis.
2.10 | Ingenuity pathway analysis
miRNA profiles were analysed by ingenuity pathway analysis (IPA, 
version 46 901 286), using the features core analysis and miRNA 
target filter. All miRNAs regulated with a FDR ≤ 0.1 were included. 
miRNA target filters were set to dendritic cell maturation, Th1 re‐
sponse and Th2 response, and only experimentally observed or predic‐
tion with high confidence targets were considered.
2.11 | Isolation of small EVs by size‐exclusion 
chromatography
qEV original columns (Izon Biosciences, Oxford, UK) were used ac‐
cording to the manufacturer’s instructions. 10 mL of basal medium or 
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apical surface wash from pools of cultures (or 3 mL of human nasal 
lavage) were preconcentrated by 10 kDa Amicon Ultra‐4 Filter Units 
(Merck Milipore) centrifuging at 4000 g for 20 minutes. The remain‐
ing suspension was filtered through a 0.2 µm filter (Merck Milipore), 
adjusted to 500 µL and applied on qEV columns. We collected frac‐
tions 1‐6 (3 mL), 7‐9 (1.5 mL), and 10‐15 (3 mL) in separate tubes. 
Fraction 7‐9 (EV‐containing) was again concentrated via Amicon fil‐
ters for further use.
2.12 | Clinical subjects
Children with mild‐to‐moderate or severe asthma and healthy con‐
trols were recruited at the Pediatric Allergology & Pulmonology out‐
patient clinic of IBIM CNR, Palermo, Italy. Included children had a 
mean age of 11 years and were selected based on doctor‐diagnosed 
asthma present for at least one year, according to ERS/ATS guidelines 
(Table 1). 12 age‐matched subjects without history of asthma, wheez‐
ing, or allergy (skin prick test negative) were assessed as healthy 
controls.
2.13 | Nasal lavages
6 mL of sterile saline fluid was injected into the nostrils, and the 
flow‐through was collected in a separate tube. Cell‐free supernatant 
was obtained by centrifuging for 10 minutes at 300 g and 4°C and 
was frozen at −80°C until further use.
2.14 | Statistical analysis
All statistical analysis was performed in GraphPad Prism 6. We used 
unpaired t test with Welsh’s correction for analyzing in vitro experi‐
ments and Mann‐Whitney U test for clinical data. A P‐value ≤ .05 
was considered statistically significant. Correlations of two param‐
eters were analysed by Spearman correlation analysis. For multiple 
comparisons, P‐values were adjusted by Bonferroni correction for 
the number of comparisons.
3  | RESULTS
3.1 | Primary NHBE cells secrete small EVs to the 
apical and basal side
To investigate the sEV‐miRNA secretion of the airway epithelium, we 
cultured primary NHBE cells at the air‐liquid interface (ALI) (Figure 1A). 
After 28 days, the differentiated epithelium was pseudostratified con‐
taining both ciliated and secretory cell types (Figure 1B). Treatment 
with IL‐13 from d14‐d28 increased goblet cells and mucus, confirmed 
by histology of membrane cross sections (Figure 1B) and increased 
gene expression of Mucin5AC (MUC5AC) and Calcium‐activated chlo‐
ride channel (CLCA1) (Figure 1C). In contrast, the markers Forkhead 
Box J1 (FOXJ1) for ciliated cells and Clara Cell 10kDa protein (CC10) for 
club cells decreased by IL‐13 treatment (Figure 1C). Early IL‐13 treat‐
ment (d0‐d14) followed by normal medium for the remaining 14 days, 
TA B L E  1   Clinical and population characteristics





No. 9 8 10
Population characteristics    
Female sex, no. (%) 5 (55.6) 3 (37.5) 1 (10.1)
Ethnicity Caucasian Caucasian Caucasian
Age (y) 11.00 (7.50‐12.00) 11.00 (9.00‐13.00) 1 0.50 (09.00‐12.00)
BMI (kg/m2) 18.96 (17.65‐20.19) 18.28 (16.58‐21.98) 18.34 (15.61‐22.63)
Smoking at home, no. (%) 1 (11.11) 5 (62.50) 3 (30.00)
Clinical characteristics    
FEV1%pred (%) 110.9 (78.60‐118.4) 83.60 (80.53‐102.4) 83.10 (77.88‐89.45)
FEV1/FVC%pred (%) 103.7 (91.69‐107.00) 94.43 (91.33‐102.5) 97.80 (92.98‐105.20)
FEF25‐75%pred (%) 99.94 (78.88‐108.10) 84.49 (64.28‐91.84) 81.75 (65.86‐92.46)
Serum IgE [U/ml] 0.00 (0‐0) 326.0 (101.40‐421.00) 131.60 (42.29‐1009)
Blood Eosinophils (%) 0.00 (0‐0) 0.58 (0.44‐6.60) 1 (0.65 ‐ 17.65)
Oral FeNO (ppb) 0.00 (0‐0) 19.5 (7.5‐37.75) 9 (5.75‐11.75)$
Nasal nNO (ppb) 0.00 (0‐0) 202 (93.00‐2007.00) 2050 (347.00‐2057.00)
Skin prick test to Dermatophagoides pt, SPT+ (‐) 0 (9) 8 (0) 7 (3)
Medication (none, ICS, ICSLABA) 9—0—0 0—2—6 0—0—10
Note: No significant differences between mild‐to‐moderate/severe asthma vs healthy controls (Mann‐Whitney U test, P < .05)
Abbreviations: n.a., not assessed.
$Mann‐Whitney U test P < .05 vs mild‐to‐moderate asthma 
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allowed cells to partly regenerate this phenotype (Figure 1A‐C). As 
NHBE cells have a distinct apical to basal polarity, we isolated EVs 
from apical surface washes and basal culture medium by precipita‐
tion (Figure 1D). Nanoparticle tracking analysis (NTA) (Figure 1E) and 
transmission electron microscopy (TEM) (Figure 1F) confirmed the 
presence of small (<200 nm) EVs both apically and basally. Western 
blot analysis revealed that basal sEVs were positive for the EV‐marker 
Alix and in part CD63 (Figure 1G), while markers on apical sEVs could 
not be detected via Western blot due to insufficient protein levels 
(Figure 1‐E‐G).
3.2 | IL‐13 treatment alters the miRNA content of 
epithelial sEVs
Next, we profiled the expression of 384 miRNAs each in apical and 
basal sEVs from control, early IL‐13‐ and late IL‐13‐treated cells. In 
F I G U R E  1   Primary bronchial epithelial cells secrete small extracellular vesicles (EVs) to the apical and basal side. A, Scheme of the air‐
liquid interface differentiation. B, PAS staining of membrane cross sections (representative images of 3 different donors). C, RT‐qPCR for 
cell‐type specific genes; n = 3 different experiments with 3 different NHBE donors; dCp = (Cptarget − Cpreference gene), lower value indicates 
higher expression, thus displayed on reversed y‐axis in graph). ****P < .001, **P < .01, *P < .05, unpaired t test with Welch’s correction. D, 
sEVs were isolated from apical surface wash or basal culture medium by precipitation. E, Vesicle concentration (left panel) and vesicle size 
(right panel) assessed by nanoparticle tracking analysis. F, Transmission electron microscopy (representative images shown of n = 3 isolation 
of 3 different donors). G, Western blot for Alix, CD63, and CD9 (showing n = 3 different donors) and corresponding stain‐free image 
showing total protein content
d14
normal medium
+ IL-13 (5 ng/mL) 
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total, 47 miRNAs were expressed in EVs with a Cp ≤ 35. In apical 
sEVs of early IL‐13‐treated cells six miRNAs were significantly altered 
compared to control cells, while there was none that reached sta‐
tistical significance (in apical EVs) upon late IL‐13 treatment (cut‐off 
false detection rate (FDR)<0.1) (Figure 2A). In basal EVs, 18 miRNAs 
were significantly altered in basal EVs upon early IL‐13 treatment and 
16 due to late IL‐13 treatment (Figure 2 A, B, Table S2). Notably, the 
majority of miRNAs were downregulated, with miR‐92b showing the 
strongest regulation (logFC −6.46 in basal EVs after late IL‐13 treat‐
ment, FDR = 0.06) (Figure 2B). Ingenuity pathway analysis (IPA) identi‐
fied that IL‐13‐induced alterations of miRNA levels in both apical and 
basal sEVs were most significantly associated with inflammatory dis‐
ease (P‐value range of: basal sEVs (d0‐d14) = 3.11e‐02‐2.27e‐11; basal 
sEVs (d14‐d28) = 2.88e‐02‐2.14e‐09; apical sEVs (d0‐d14) = 4.90e‐
02‐3.00e‐04) and inflammatory response (Table S3), while the predic‐
tion was more significant for basal profiles (Figure 2C, Table S3).
3.3 | Confirmation of changes in sEVs isolated by 
size‐exclusion chromatography (SEC)
Precipitation‐based EV isolation co‐precipitates free protein‐
bound miRNA that are not enclosed in EVs.17 To confirm that 
significantly regulated miRNAs are truly EV‐associated and can 
therefore be transferred within the lung microenvironment, we 
isolated sEVs by SEC, having a superior separation from residual 
protein.18 SEC sEVs were < 200 nm, express CD63, CD9, and CD81 
(Figure S1C, S2), but both particle concentrations and marker 
expression did not change upon IL‐13 treatment (Figure S1 A‐C, 
S2). In line with precipitated sEVs, IL‐13 induced a strong signifi‐
cant decrease of miR‐125a‐5p in apical sEVs (FCmiR‐125a‐5p = 0.28; 
P = .011) and of miR‐92b in both apical (FCmiR‐92b = 0.07; P = .0001) 
and basal sEVs (FCmiR‐92b = 0.52, P = .045) (Figure S1 C). miR‐210 
and miR‐34a levels were decreased in both miRNAs in apical sEVs 
in two of the three NHBE donors (not statistically significant). miR‐
542‐5p and miR‐345 (trendwise) were decreased in basal sEVs 
(FCmiR‐345 = 0.52; P = .06, FCmiR‐542‐5p = 0.228; P = .009) after IL‐13 
treatment (Figure S1 C).
3.4 | sEV‐miRNA levels in nasal lavages correlate 
with airway obstruction in children
To translate our findings to the human situation, we assessed the 
miRNA levels in sEVs from nasal lavages of children with mild‐to‐
moderate (AM) or severe asthma (AS) compared to healthy controls 
F I G U R E  2   IL‐13 treatment alters the miRNA content of epithelial EVs. A, Plots showing significantly changed miRNAs in basal EVs and 
apical EVs upon early (d0‐d14) or late (d14‐d28) IL‐13 treatment of NHBE cells (cut‐off FDR = 0.1). B, Corresponding heatmaps of IL‐13 
regulated miRNAs in EVs. Red indicates downregulation upon IL‐13 treatment vs control, green indicates upregulation. Selected candidate 
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(HC). Concentration and size of SEC‐isolated EVs from nasal lav‐
age did not differ among the patient groups (Figure 3A). All previ‐
ously identified miRNAs were expressed in nasal lavage sEVs, while 
miR‐542‐5p showed a significant decrease in AM and AS groups 
(Figure 3B). miR‐92b (Spearman r = −.55, Padj = .02) and miR‐210 
(Spearman r = −.58, Padj = .01) levels significantly correlated with 
F I G U R E  3   Small sEV‐miRNA levels in nasal washes correlate with airway obstruction in children. A, Vesicle concentration (left panel) 
and vesicle size (right panel) assessed by nanoparticle tracking analysis from nasal wash of healthy control children (HC) (n = 9), and children 
with mild‐to‐moderate asthma (AM) (n = 8) or severe asthma (AS) (n = 10); Mann‐Whitney U test vs HC. B RT‐qPCR of candidate miRNAs of 
isolated sEVs plotted as dCp values (dCp = (Cptarget − Cpreference miRNA), lower value indicates higher expression, thus displayed on reversed 
y‐axis in graph). Mann‐Whitney U test vs HC. C Spearman correlations of miRNA levels (plotted as dCp) in sEVs from nasal washes with 
FEV1FVC%pred (upper panel) and FEF25‐75%pred (lower panel); Spearman r value and adjusted P values indicating significance of correlation are 
shown in the respective graphs. White dots represent healthy controls, gray dots mild‐to‐moderate asthma, and black dots severe asthma. 
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the lung function parameter FEV1FVC%pre, and we could observe a 
strong trend for miR‐34a (Spearman r = −0.51, Padj = .051) as well. 
Of note, the latter miRNA also significantly correlated with a param‐
eter for small airway obstruction19 FEF25‐75%pred (Spearman r = −.58, 
Padj = .01) together with miR‐210 (Spearman r = −.58, Padj = .01) 
and trendwise miR‐92b (Spearman r = −0.48, Padj = .09) (Figure 3C, 
Table 2). This indicates that lower miR‐34a, miR‐92b, and miR‐210 
levels in nasal lavage sEVs are associated with airway obstruction in 
children enrolled in this study.
3.5 | Altered miRNA levels in sEVs could influence 
Th polarization by DCs
As pediatric asthma is predominantly allergic (Th2 dominant), we 
used IPA to search for targets of the miRNAs influencing the matu‐
ration of DCs or the polarization of Th cells. We identified a putative 
network of miR‐34a, miR‐92b, and miR‐210 and their targets associ‐
ated with both DC maturation and Th2 polarization (Figure 4). Among 
others, miR‐210 was predicted to target Runt Related Transcription 
Factor 3 (RUNX3), or Phosphoinositide‐3‐Kinase Regulatory Subunit 5 
(PIK3R5), miR‐34a targets NOTCH1, NOTCH2, Jagged 1 (JAG1), and 
IKAROS Family Zinc Finger 1 (IKZ‐F1). The latter is also predicted for 
miR‐92b along with bone morphogenic protein receptor 2 (BMPR2). 
In theory, as the three miRNAs are decreased in sEVs upon IL‐13 
treatment or in asthma, all of these factors would presumably in‐
crease, potentially enhancing DC maturation and Th2 differentiation 
(Figure 4).
4  | DISCUSSION
We here report for the first time that primary NHBE cells secrete 
sEVs apically and basally. sEVs derived by precipitation of IL‐13‐
treated epithelial cells contained decreased levels of miR‐92b, 
miR‐34a, and miR‐210. A lower expression of miR‐34a, miR‐92b, 
and miR‐210 levels in sEVs in nasal lavages from children was as‐
sociated with obstruction of large (FEV1FVC%pred) and small airways 
(FEF25‐75%pred).
19 All three miRNAs were predicted to be involved in 
regulating Th2 differentiation and DC maturation. In summary, our 
data suggest that airway epithelial miRNA secretion via sEVs might 
be implicated in the development of asthma.
Virtually every cell type can produce EVs,20 including the air‐
way epithelium.21‐23 Here, we isolated sEVs from both apical surface 
TA B L E  2   Correlation of sEV‐miRNA levels with clinical characteristics
Parameter FEV1FVC%pred FEV1%pred FEF2575%pred Nasal nNO [ppb] Serum IgE [U/mL]
Blood eosino‐
phils [%]
dCP EV miR‐34a −0.511 (0.051) −0.245 (0.860) −0.579 (0.013)* −0.472 (0.468) 0.414 (0.660) 0.355 (0.933)
dCP EV miR‐92b −0.550 (0.023)* −0.012 (1.000) −0.480 (0.087) −0.295 (0.926) 0.568 (0.214) 0.255 (0.992)
dCP EV 
miR‐125a‐5p
−0.345 (0.478) −0.123 (0.998) −0.400 (0.271) −0.583 (0.177) 0.532 (0.301) 0.255 (0.992)
dCP EV miR‐210 −0.582 (0.011)* −0.002 (1.000) −0.596 (0.008)** 0.515 (0.345) −0.250 (0.974) 0.164 (1.000)
dCP EV miR‐211 0.035 (1.000) −0.068 (1.000) 0.199 (0.959) 0.038 (01.000) −0.029 (1.000) −0.136 (1.000)
dCP EV miR‐345 −0.168 (0.984) −0.174 (0.979) −0.268 (0.787) −0.119 (1.000) −0.288 (0.9374) −0.191 (0.999)
dCP EV miR‐422 −0.410 (0.241) 0.167 (0.9841) −0.341 (0.493) −0.063 (1.000) −0.014 (1.000) 0.118 (1.000)
dCP EV miR‐542‐3p −0.161 (0.988) −0.312 (0.618) −0.499 (0.063) −0.351 (0.827) −0.334 (0.862) −0.0775 (1.000)
Note: Table lists spearman r correlation co‐efficient (adjusted P‐value). Significant correlations are marked in bold. miRNA levels were assessed in 
sEVs from nasal washes of n = 9 healthy controls, n = 8 mild‐to‐moderate asthma and n = 10 severe asthma.
*indicates P < 0.05. 
**indicates P < 0.01. 
F I G U R E  4   miR‐92b, miR‐34a, and miR‐210 are predicted to 
regulate Th2 differentiation and dendritic cell maturation. IPA‐
predicted network of miR‐92b, miR‐34a, and miR‐210 showing 
predicted targets and their association with biological functions 
Th2 differentiation and dendritic cell maturation. Red indicates 
decrease on array, and green indicates predicted increase
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washes and basal medium of primary NHBE cells and confirmed this 
by TEM, NTA, and Western blot. We did not further subclassify them 
into, that is, exosomes, as pure isolations thereof are virtually impossi‐
ble,20 and we here were interested to show that the entity of sEVs and 
their cargo, that also coincide in vivo, is involved in asthma develop‐
ment. Concentration, size, or marker expression did not change upon 
IL‐13 treatment, demonstrating that it specifically affected the miRNA 
content. The expression of identified miRNAs was confirmed in SEC‐
isolated sEVs free from contaminating (RNA‐binding proteins),6 indi‐
cating that the miRNAs could potentially be transferred between cells.
It is known that sEV‐miRNA levels in BALF of patients with 
asthma differ from healthy controls, and some miRNAs significantly 
correlated with lung function (FEV1).
24 We can now add that miRNA‐
containing sEVs can be isolated from nasal lavages, being easier to 
obtain and less invasive, which is particularly important in pediatric 
patients. As asthma remains difficult to diagnose in young children, it 
is intriguing to speculate that sEV‐miRNA signatures in nasal lavages 
could be used accordingly in the future.
The IPA prediction that miR‐34a, miR‐92b, and miR‐210 affect 
DC function and Th2 polarization is supported by experimental evi‐
dence from others: miR‐34a is enclosed in sEVs 25 and regulates DC 
function and maturation via targeting the Wingless/Integrase (Wnt) 
pathway.26,27 miR‐34a increases in conventional DCs decrease upon 
antigen encounter and its overexpression suppressed CD4+ T‐cell 
polarization.27 In rheumatoid arthritis, miR‐34a is increased in DCs, 
and knock‐out animals had less severe disease and less IL‐17A,28 
again highlighting its important role in DC function. A decrease in 
miR‐34a in airway epithelial sEVs could therewith potentially en‐
hance CD4+ Th2‐polarization in asthma.
miR‐210 has been found in EVs,29 is increased in tolerogenic 
and activated DCs,30 and further involved in regulatory T‐cell func‐
tion via targeting Forkhead Box 3 (FOXP3).31 An overexpression of 
miR‐210 resulted in immune dysfunction and less immunosuppres‐
sive capacity of Tregs in psoriasis vulgaris,32 and miR‐210 induces 
Th1 and Th17 differentiation but inhibits Th2 in psoriasis.33 This is 
in line with our IPA prediction, that an IL‐13‐induced decrease of 
miR‐210 in sEVs could increase Th2 polarization by DCs. This miRNA 
has been shown to be increased in sEVs isolated from nasal mucus of 
adults with allergic rhinitis compared to healthy controls,34 suggest‐
ing a disease specific regulation of nasal sEV‐miRNA levels.
miR‐92b has not been described in relation to the immune system 
or asthma, but regulates epithelial‐to‐mesenchymal transition (EMT) by 
targeting SMAD3 in nasopharyngeal carcinoma.35 Further, it is present 
in serum exosomes serving as biomarker for acute heart failure.36 The 
correlation with airway obstruction in children and its IPA‐predicted 
targets relevant for Th2 polarization such as IKZF1 and BMPR2 strongly 
suggest a new role for this particular miRNA in the development of 
asthma. Additionally, airway remodeling and loss of airway integrity in 
asthma is a type of EMT37 influencing airway obstruction and hyper 
reactivity, which might be regulated by epithelial sEVs via miR‐92b.
Aside from miRNAs, sEVs contribute to asthma pathogenesis 
via other mechanisms. EVs from the airway epithelium present 
allergens on MHCII molecules, inducing tolerance or an active 
immune response depending on the status of the epithelium.38‐40 
BALF sEVs include leukotrienes and increased cytokine release 
from an airway epithelial cell line,41 while sEVs released from an 
IL‐13‐treated bronchial epithelial cell line acted pro‐inflammatory 
in mice and induced macrophage chemotaxis.23 Furthermore, EVs 
isolated from nasal secretions of children with asthma or chronic 
rhinitis increased immune cell trafficking, due to an altered protein 
cargo.42 The actions of airway epithelial sEVs are thus multi‐potent 
and supposedly contribute with an entity of different molecules to 
asthma pathogenesis.
We would like to acknowledge some limitations of our study. 
We here only use NHBE cells from healthy individuals treated with 
IL‐13 to induce an “asthma‐like” phenotype, as we were interested 
to study the early molecular changes in the secretions of the air‐
way epithelium, which is not possible when using cells from patients 
with an established disease. Nonetheless, we were able to confirm 
the expression of all miRNAs in sEVs isolated from nasal lavages, 
and three miRNAs significantly correlated with airway obstruction 
in children. Of note, nasal epithelial cells have been suggested as 
a less‐invasive surrogate for bronchial epithelial cells, due to high 
similarities in their gene expression levels.43 Second, the numbers 
of included patients and NHBE donors are low and findings need to 
be confirmed in larger studies. Third, we are aware that the Western 
blot‐based characterization is relatively poor due to very low yield 
of proteins isolated from sEVs from primary cell cultures (espe‐
cially the apical washes).6 However, we here followed the standard 
isolation protocols with which both methods have been shown to 
isolate intact sEVs expressing relevant markers before44‐46 and we 
could confirm the presence of CD81, CD63, and CD9 on SEC‐iso‐
lated sEVs by a more sensitive flow cytometry approach. Fourth, a 
functional transfer of miRNA‐containing sEVs between the airway 
epithelium and DCs needs to be shown in future studies. Albeit, as 
EVs contain surface molecules such as HLA‐DR,47 we figured that 
the cellular interaction might be subject‐specific and thus question 
the use of DCs from different human donors. It has however been 
shown several times that miRNAs can be functionally transferred 
to target cells 48‐53 and that DC function is modulated by EVs.54‐
56 Thus, it is intriguing to speculate that sEVs‐associated epithelial 
miRNAs are involved in regulating the immune responses by under‐
lying DCs. Based on our theoretical IPA‐model, decreased levels 
of miR‐92b, miR‐210, and miR‐34a in epithelial‐derived sEVs upon 
asthma development, would allow DCs to polarize Th2 cells, per‐
petuating the asthmatic phenotype in the lung microenvironment. 
While the direct transfer of these miRNAs to DCs (or other target 
cells) needs experimental confirmation in follow‐up studies, our re‐
sults nonetheless represent a first and encouraging insight into a 
potential role of epithelial EV‐associated miRNAs in the lung micro‐
environment upon asthma development.
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